Mohammad Hossein Boskabady | Pharmacology | Best Researcher Award Posted on 27/08/202429/08/2024 by ScienceFather Dr. Mohammad Hossein Boskabady | Pharmacology | Best Researcher Award Professor of Clinical Physiology, Mashhad University of Medical Sciences, Iran Dr. Mohammad Hossein Boskabady is a distinguished researcher in the field of Pharmacology, renowned for his innovative contributions and groundbreaking research. With a strong background in pharmacological sciences, Dr. Boskabady’s work focuses on exploring the therapeutic potentials and mechanisms of various compounds. His extensive research has significantly advanced the understanding of drug actions and interactions, earning him recognition as a leading figure in pharmacological research. Dr. Boskabady’s commitment to scientific excellence and his impactful discoveries make him a deserving candidate for the Best Researcher Award. Profile Scopus Profile Education Dr. Mohammad Hossein Boskabady’s academic journey began with his primary education in Boskabad, Khorasan, followed by high school in Gonabad, Khorasan, Iran. He earned his M.D. from Mashhad University of Medical Sciences. Dr. Boskabady furthered his studies as a postgraduate student in Physiology at University College London before completing his Ph.D. in Medicine at Charing Cross and Westminster Medical School, where he focused his thesis on the responsiveness of human bronchi to pharmacological agonists and antagonists. With a strong commitment to advancing pharmacological research, Dr. Boskabady aims to continue his research and lecturing at the university level, contributing to the field through innovative studies and academic excellence. Employment Dr. Mohammad Hossein Boskabady’s professional career began as a Doctor in the Emergency and Casualty Department at Imam Reza Hospital in Mashhad, Iran. Concurrently, he served as a Lecturer in Clinical Physiology at Ghaem Medical Centre, Mashhad University of Medical Sciences. Over the years, Dr. Boskabady advanced through academic ranks, holding positions as Assistant Professor, Associate Professor, and ultimately Professor in Clinical Physiology at the same institution. His extensive experience in both clinical practice and academic teaching underscores his significant contributions to the field of pharmacology and clinical physiology. Awards Dr. Mohammad Hossein Boskabady has been recognized for his outstanding contributions to research in Basic Medical Sciences with numerous prestigious awards. From 2000 to 2005, he won First Prizes at the Mashhad University of Medical Sciences Festival every year, and also received Second Prizes at the Razi National Festival in 2002 and 2006. He was honored as a Selected Researcher in Basic Medical Sciences for Khorasan Province in 2007 and 2008. Dr. Boskabady continued to excel, securing First Prizes at the Mashhad University of Medical Sciences Festival from 2009 to 2011, and was awarded Best Researcher at the same festival in 2012, 2013, 2016, and 2019. In 2021, he was recognized as a Selected Researcher at the School of Medicine, Mashhad University of Medical Sciences. Additionally, in November 2017, he was distinguished as a 1% world scientist by Essential Science Indicators (ESI), highlighting his global impact in the field Official Posts Dr. Mohammad Hossein Boskabady has held several significant roles throughout his career, reflecting his dedication and leadership in the field of medical sciences. From October 1994 to December 1996, he served as Consultant to the Vice Chancellor for Research at Mashhad University of Medical Sciences. He was a member of the Occupational Health Committee in Khorasan Province from November 1995 to October 1998 and also held the position of Director of International Affairs at Mashhad University of Medical Sciences from October 1996 to April 1999. Additionally, Dr. Boskabady was a member of the Scholarship Council from October 1997 to April 1999. He led the Physiology Department as Head from February 2000 to April 2002. Dr. Boskabady has been a member of the Editorial Board of the Journal of Basic Medical Sciences since October 1995 and has been involved with the Examination Board in Physiology for the Ministry of Health and Medical Education since August 2000. His other roles include serving on various research committees and councils at Mashhad University of Medical Sciences and acting as Secretary General for the 18th Congress of Iranian Physiology and Pharmacology in 2007. Since August 2011, he has been the Director of the Applied Biomedical Research Center at Mashhad University of Medical Sciences, and he has also served as Research Deputy for the School of Medicine from August 2011 to December 2013. Publication Top Notes Boskabady, M. H., & Snashall, P. D. (1992). Enhanced muscarinic receptor blockade with atropine in the asthmatic tracheobronchial tree: Evidence for increased drug delivery in asthma. American Review of Respiratory Disease, 145(5), 756-761. DOI: 10.1164/ajrccm/145.5.756. Boskabady, M. H., & Snashall, P. D. (1996). Short term variation of atropine blockade in the tracheobronchial tree of asthmatic subjects. Medical Journal of the Islamic Republic of Iran, 10(3), 183-189. DOI: 10.17102/mjiri.1996.0108. Boskabady, M. H., & Snashall, P. D. (1997). Enhanced histamine H1 receptor blockade with chlorpheniramine in the asthmatic tracheobronchial tree: Further evidence for increased drug delivery in asthma. Medical Journal of the Islamic Republic of Iran, 11(2), 115-122. DOI: 10.17102/mjiri.1997.0063. Boskabady, M. H., & Shhabi, M. (1997). Bronchodilatory and anticholinergic effects of Nigella sativa on isolated guinea pig tracheal chains. Iranian Journal of Medical Sciences, 22(4), 127-133. DOI: 10.30476/ijms.1997.0549. Boskabady, M. H., Rakhshandah, H., & Moetamedshariati, V. (1998). Bronchodilatory and anticholinergic effects of Carum copticum on isolated guinea pig tracheal chains. Medical Journal of the Islamic Republic of Iran, 11(5), 329-334. DOI: 10.17102/mjiri.1998.0134. Boskabady, M. H., & Harati, M. (1998). Increased histamine H1 receptor blockade by chlorpheniramine in tracheal chains of asthmatic guinea-pigs. Medical Journal of the Islamic Republic of Iran, 12(2), 265-271. DOI: 10.17102/mjiri.1998.0089. Boskabady, M. H., & Talebi, M. (1999). Bronchodilatory and anticholinergic effects of Carum carvi on isolated guinea pig tracheal chains. Medical Journal of the Islamic Republic of Iran, 12(3), 345-351. DOI: 10.17102/mjiri.1999.0154. Boskabady, M. H., & Adel-Kardan, S. (1999). Increased muscarinic receptor blockade by atropine in tracheal chains of ovalbumin-sensitized guinea-pigs. Pharmacology, 58(6), 300-308. DOI: 10.1159/000029652. Boskabady, M. H., & Shikhi, J. (2000). Inhibitory effect of Carum copticum on histamine (H1) receptors of isolated guinea pig tracheal chains. Journal of Ethnopharmacology, 69(2), 217-227. DOI: 10.1016/S0378-8741(99)00244-3. Boskabady, M. H., & Simaei, N. (1999). Prevalence of asthma among young adults (high school students) in the city of Mashhad (north east of Iran). Iranian Journal of Medical Sciences, 24(1), 48-52. DOI: 10.30476/ijms.1999.0442. Boskabady, M. H., & Snashall, P. D. (2000). Bronchial responsiveness to beta-adrenergic stimulation and enhanced beta blockade in asthma. Respirology, 5(2), 111-118. DOI: 10.1046/j.1440-1843.2000.00243.x. Boskabady, M. H., & Moemeni, A. (2000). Stimulatory effect of Carum copticum on beta2 adrenoceptors of isolated guinea pig tracheal chains. Medical Journal of the Islamic Republic of Iran, 13(3), 273-278. DOI: 10.17102/mjiri.2000.0192. Boskabady, M. H., Karbandy, S., & Abedinzadah, A. (2000). The effects of arterial O2 saturation and heart rate on blood pressure. Medical Journal of the Islamic Republic of Iran, 14(2), 37-41. DOI: 10.17102/mjiri.2000.0200. Boskabady, M. H., & Karimian, M. (2000). Prevalence of asthma among guidance school students (aged 11-16 years) in the city of Mashhad (north east of Iran). Archives of Iranian Medicine, 3(3), 165-169. DOI: 10.30476/aim.2000.0109. Boskabady, M. H., & Hosaini, M. (2000). Effect of patient education and regular PEF measurement on self-management of asthma. Iranian Journal of Allergy, Asthma, and Immunology, 1(2), 159-164. DOI: 10.30476/ijaai.2000.0111. Boskabady, M. H., & Ramazani, M. (2001). Relaxant effect of Pimpinella anisum on isolated guinea pig tracheal chains and its possible mechanism(s). Journal of Ethnopharmacology, 74(1), 83-88. DOI: 10.1016/S0378-8741(00)00382-5. Boskabady, M. H., Keshmiri, M., Banihashemi, B., & Anvary, K. H. (2002). Lung function values in healthy non-smoking urban adults in Iran. Respiration, 69(4), 320-326. DOI: 10.1159/000065155. Boskabady, M. H., & Klahdoz, G. H. (2002). Prevalence of asthma symptoms among the adult population in the city of Mashhad (north-east of Iran). Respirology, 7(3), 267-272. DOI: 10.1046/j.1440-1843.2002.00413.x. Boskabady, M. H., & Shirmohammadi, B. (2002). Effect of Nigella sativa on isolated guinea pig trachea. Archives of Iranian Medicine, 5(2), 103-107. DOI: 10.30476/aim.2002.0145. Boskabady, M. H., & Shiravi, N. (2002). Inhibitory effect of Nigella sativa on histamine (H1) receptors of isolated guinea pig tracheal chains. Pharmaceutical Biology, 40(8), 596-602. DOI: 10.1076/1388-0209(200208)4008-0005.
Dr. Mohammad Hossein Boskabady is a distinguished researcher in the field of Pharmacology, renowned for his innovative contributions and groundbreaking research. With a strong background in pharmacological sciences, Dr. Boskabady’s work focuses on exploring the therapeutic potentials and mechanisms of various compounds. His extensive research has significantly advanced the understanding of drug actions and interactions, earning him recognition as a leading figure in pharmacological research. Dr. Boskabady’s commitment to scientific excellence and his impactful discoveries make him a deserving candidate for the Best Researcher Award. Profile Scopus Profile Education Dr. Mohammad Hossein Boskabady’s academic journey began with his primary education in Boskabad, Khorasan, followed by high school in Gonabad, Khorasan, Iran. He earned his M.D. from Mashhad University of Medical Sciences. Dr. Boskabady furthered his studies as a postgraduate student in Physiology at University College London before completing his Ph.D. in Medicine at Charing Cross and Westminster Medical School, where he focused his thesis on the responsiveness of human bronchi to pharmacological agonists and antagonists. With a strong commitment to advancing pharmacological research, Dr. Boskabady aims to continue his research and lecturing at the university level, contributing to the field through innovative studies and academic excellence. Employment Dr. Mohammad Hossein Boskabady’s professional career began as a Doctor in the Emergency and Casualty Department at Imam Reza Hospital in Mashhad, Iran. Concurrently, he served as a Lecturer in Clinical Physiology at Ghaem Medical Centre, Mashhad University of Medical Sciences. Over the years, Dr. Boskabady advanced through academic ranks, holding positions as Assistant Professor, Associate Professor, and ultimately Professor in Clinical Physiology at the same institution. His extensive experience in both clinical practice and academic teaching underscores his significant contributions to the field of pharmacology and clinical physiology. Awards Dr. Mohammad Hossein Boskabady has been recognized for his outstanding contributions to research in Basic Medical Sciences with numerous prestigious awards. From 2000 to 2005, he won First Prizes at the Mashhad University of Medical Sciences Festival every year, and also received Second Prizes at the Razi National Festival in 2002 and 2006. He was honored as a Selected Researcher in Basic Medical Sciences for Khorasan Province in 2007 and 2008. Dr. Boskabady continued to excel, securing First Prizes at the Mashhad University of Medical Sciences Festival from 2009 to 2011, and was awarded Best Researcher at the same festival in 2012, 2013, 2016, and 2019. In 2021, he was recognized as a Selected Researcher at the School of Medicine, Mashhad University of Medical Sciences. Additionally, in November 2017, he was distinguished as a 1% world scientist by Essential Science Indicators (ESI), highlighting his global impact in the field Official Posts Dr. Mohammad Hossein Boskabady has held several significant roles throughout his career, reflecting his dedication and leadership in the field of medical sciences. From October 1994 to December 1996, he served as Consultant to the Vice Chancellor for Research at Mashhad University of Medical Sciences. He was a member of the Occupational Health Committee in Khorasan Province from November 1995 to October 1998 and also held the position of Director of International Affairs at Mashhad University of Medical Sciences from October 1996 to April 1999. Additionally, Dr. Boskabady was a member of the Scholarship Council from October 1997 to April 1999. He led the Physiology Department as Head from February 2000 to April 2002. Dr. Boskabady has been a member of the Editorial Board of the Journal of Basic Medical Sciences since October 1995 and has been involved with the Examination Board in Physiology for the Ministry of Health and Medical Education since August 2000. His other roles include serving on various research committees and councils at Mashhad University of Medical Sciences and acting as Secretary General for the 18th Congress of Iranian Physiology and Pharmacology in 2007. Since August 2011, he has been the Director of the Applied Biomedical Research Center at Mashhad University of Medical Sciences, and he has also served as Research Deputy for the School of Medicine from August 2011 to December 2013. Publication Top Notes Boskabady, M. H., & Snashall, P. D. (1992). Enhanced muscarinic receptor blockade with atropine in the asthmatic tracheobronchial tree: Evidence for increased drug delivery in asthma. American Review of Respiratory Disease, 145(5), 756-761. DOI: 10.1164/ajrccm/145.5.756. Boskabady, M. H., & Snashall, P. D. (1996). Short term variation of atropine blockade in the tracheobronchial tree of asthmatic subjects. Medical Journal of the Islamic Republic of Iran, 10(3), 183-189. DOI: 10.17102/mjiri.1996.0108. Boskabady, M. H., & Snashall, P. D. (1997). Enhanced histamine H1 receptor blockade with chlorpheniramine in the asthmatic tracheobronchial tree: Further evidence for increased drug delivery in asthma. Medical Journal of the Islamic Republic of Iran, 11(2), 115-122. DOI: 10.17102/mjiri.1997.0063. Boskabady, M. H., & Shhabi, M. (1997). Bronchodilatory and anticholinergic effects of Nigella sativa on isolated guinea pig tracheal chains. Iranian Journal of Medical Sciences, 22(4), 127-133. DOI: 10.30476/ijms.1997.0549. Boskabady, M. H., Rakhshandah, H., & Moetamedshariati, V. (1998). Bronchodilatory and anticholinergic effects of Carum copticum on isolated guinea pig tracheal chains. Medical Journal of the Islamic Republic of Iran, 11(5), 329-334. DOI: 10.17102/mjiri.1998.0134. Boskabady, M. H., & Harati, M. (1998). Increased histamine H1 receptor blockade by chlorpheniramine in tracheal chains of asthmatic guinea-pigs. Medical Journal of the Islamic Republic of Iran, 12(2), 265-271. DOI: 10.17102/mjiri.1998.0089. Boskabady, M. H., & Talebi, M. (1999). Bronchodilatory and anticholinergic effects of Carum carvi on isolated guinea pig tracheal chains. Medical Journal of the Islamic Republic of Iran, 12(3), 345-351. DOI: 10.17102/mjiri.1999.0154. Boskabady, M. H., & Adel-Kardan, S. (1999). Increased muscarinic receptor blockade by atropine in tracheal chains of ovalbumin-sensitized guinea-pigs. Pharmacology, 58(6), 300-308. DOI: 10.1159/000029652. Boskabady, M. H., & Shikhi, J. (2000). Inhibitory effect of Carum copticum on histamine (H1) receptors of isolated guinea pig tracheal chains. Journal of Ethnopharmacology, 69(2), 217-227. DOI: 10.1016/S0378-8741(99)00244-3. Boskabady, M. H., & Simaei, N. (1999). Prevalence of asthma among young adults (high school students) in the city of Mashhad (north east of Iran). Iranian Journal of Medical Sciences, 24(1), 48-52. DOI: 10.30476/ijms.1999.0442. Boskabady, M. H., & Snashall, P. D. (2000). Bronchial responsiveness to beta-adrenergic stimulation and enhanced beta blockade in asthma. Respirology, 5(2), 111-118. DOI: 10.1046/j.1440-1843.2000.00243.x. Boskabady, M. H., & Moemeni, A. (2000). Stimulatory effect of Carum copticum on beta2 adrenoceptors of isolated guinea pig tracheal chains. Medical Journal of the Islamic Republic of Iran, 13(3), 273-278. DOI: 10.17102/mjiri.2000.0192. Boskabady, M. H., Karbandy, S., & Abedinzadah, A. (2000). The effects of arterial O2 saturation and heart rate on blood pressure. Medical Journal of the Islamic Republic of Iran, 14(2), 37-41. DOI: 10.17102/mjiri.2000.0200. Boskabady, M. H., & Karimian, M. (2000). Prevalence of asthma among guidance school students (aged 11-16 years) in the city of Mashhad (north east of Iran). Archives of Iranian Medicine, 3(3), 165-169. DOI: 10.30476/aim.2000.0109. Boskabady, M. H., & Hosaini, M. (2000). Effect of patient education and regular PEF measurement on self-management of asthma. Iranian Journal of Allergy, Asthma, and Immunology, 1(2), 159-164. DOI: 10.30476/ijaai.2000.0111. Boskabady, M. H., & Ramazani, M. (2001). Relaxant effect of Pimpinella anisum on isolated guinea pig tracheal chains and its possible mechanism(s). Journal of Ethnopharmacology, 74(1), 83-88. DOI: 10.1016/S0378-8741(00)00382-5. Boskabady, M. H., Keshmiri, M., Banihashemi, B., & Anvary, K. H. (2002). Lung function values in healthy non-smoking urban adults in Iran. Respiration, 69(4), 320-326. DOI: 10.1159/000065155. Boskabady, M. H., & Klahdoz, G. H. (2002). Prevalence of asthma symptoms among the adult population in the city of Mashhad (north-east of Iran). Respirology, 7(3), 267-272. DOI: 10.1046/j.1440-1843.2002.00413.x. Boskabady, M. H., & Shirmohammadi, B. (2002). Effect of Nigella sativa on isolated guinea pig trachea. Archives of Iranian Medicine, 5(2), 103-107. DOI: 10.30476/aim.2002.0145. Boskabady, M. H., & Shiravi, N. (2002). Inhibitory effect of Nigella sativa on histamine (H1) receptors of isolated guinea pig tracheal chains. Pharmaceutical Biology, 40(8), 596-602. DOI: 10.1076/1388-0209(200208)4008-0005.
Dr. Mohammad Hossein Boskabady’s professional career began as a Doctor in the Emergency and Casualty Department at Imam Reza Hospital in Mashhad, Iran. Concurrently, he served as a Lecturer in Clinical Physiology at Ghaem Medical Centre, Mashhad University of Medical Sciences. Over the years, Dr. Boskabady advanced through academic ranks, holding positions as Assistant Professor, Associate Professor, and ultimately Professor in Clinical Physiology at the same institution. His extensive experience in both clinical practice and academic teaching underscores his significant contributions to the field of pharmacology and clinical physiology. Awards Dr. Mohammad Hossein Boskabady has been recognized for his outstanding contributions to research in Basic Medical Sciences with numerous prestigious awards. From 2000 to 2005, he won First Prizes at the Mashhad University of Medical Sciences Festival every year, and also received Second Prizes at the Razi National Festival in 2002 and 2006. He was honored as a Selected Researcher in Basic Medical Sciences for Khorasan Province in 2007 and 2008. Dr. Boskabady continued to excel, securing First Prizes at the Mashhad University of Medical Sciences Festival from 2009 to 2011, and was awarded Best Researcher at the same festival in 2012, 2013, 2016, and 2019. In 2021, he was recognized as a Selected Researcher at the School of Medicine, Mashhad University of Medical Sciences. Additionally, in November 2017, he was distinguished as a 1% world scientist by Essential Science Indicators (ESI), highlighting his global impact in the field Official Posts Dr. Mohammad Hossein Boskabady has held several significant roles throughout his career, reflecting his dedication and leadership in the field of medical sciences. From October 1994 to December 1996, he served as Consultant to the Vice Chancellor for Research at Mashhad University of Medical Sciences. He was a member of the Occupational Health Committee in Khorasan Province from November 1995 to October 1998 and also held the position of Director of International Affairs at Mashhad University of Medical Sciences from October 1996 to April 1999. Additionally, Dr. Boskabady was a member of the Scholarship Council from October 1997 to April 1999. He led the Physiology Department as Head from February 2000 to April 2002. Dr. Boskabady has been a member of the Editorial Board of the Journal of Basic Medical Sciences since October 1995 and has been involved with the Examination Board in Physiology for the Ministry of Health and Medical Education since August 2000. His other roles include serving on various research committees and councils at Mashhad University of Medical Sciences and acting as Secretary General for the 18th Congress of Iranian Physiology and Pharmacology in 2007. Since August 2011, he has been the Director of the Applied Biomedical Research Center at Mashhad University of Medical Sciences, and he has also served as Research Deputy for the School of Medicine from August 2011 to December 2013. Publication Top Notes Boskabady, M. H., & Snashall, P. D. (1992). Enhanced muscarinic receptor blockade with atropine in the asthmatic tracheobronchial tree: Evidence for increased drug delivery in asthma. American Review of Respiratory Disease, 145(5), 756-761. DOI: 10.1164/ajrccm/145.5.756. Boskabady, M. H., & Snashall, P. D. (1996). Short term variation of atropine blockade in the tracheobronchial tree of asthmatic subjects. Medical Journal of the Islamic Republic of Iran, 10(3), 183-189. DOI: 10.17102/mjiri.1996.0108. Boskabady, M. H., & Snashall, P. D. (1997). Enhanced histamine H1 receptor blockade with chlorpheniramine in the asthmatic tracheobronchial tree: Further evidence for increased drug delivery in asthma. Medical Journal of the Islamic Republic of Iran, 11(2), 115-122. DOI: 10.17102/mjiri.1997.0063. Boskabady, M. H., & Shhabi, M. (1997). Bronchodilatory and anticholinergic effects of Nigella sativa on isolated guinea pig tracheal chains. Iranian Journal of Medical Sciences, 22(4), 127-133. DOI: 10.30476/ijms.1997.0549. Boskabady, M. H., Rakhshandah, H., & Moetamedshariati, V. (1998). Bronchodilatory and anticholinergic effects of Carum copticum on isolated guinea pig tracheal chains. Medical Journal of the Islamic Republic of Iran, 11(5), 329-334. DOI: 10.17102/mjiri.1998.0134. Boskabady, M. H., & Harati, M. (1998). Increased histamine H1 receptor blockade by chlorpheniramine in tracheal chains of asthmatic guinea-pigs. Medical Journal of the Islamic Republic of Iran, 12(2), 265-271. DOI: 10.17102/mjiri.1998.0089. Boskabady, M. H., & Talebi, M. (1999). Bronchodilatory and anticholinergic effects of Carum carvi on isolated guinea pig tracheal chains. Medical Journal of the Islamic Republic of Iran, 12(3), 345-351. DOI: 10.17102/mjiri.1999.0154. Boskabady, M. H., & Adel-Kardan, S. (1999). Increased muscarinic receptor blockade by atropine in tracheal chains of ovalbumin-sensitized guinea-pigs. Pharmacology, 58(6), 300-308. DOI: 10.1159/000029652. Boskabady, M. H., & Shikhi, J. (2000). Inhibitory effect of Carum copticum on histamine (H1) receptors of isolated guinea pig tracheal chains. Journal of Ethnopharmacology, 69(2), 217-227. DOI: 10.1016/S0378-8741(99)00244-3. Boskabady, M. H., & Simaei, N. (1999). Prevalence of asthma among young adults (high school students) in the city of Mashhad (north east of Iran). Iranian Journal of Medical Sciences, 24(1), 48-52. DOI: 10.30476/ijms.1999.0442. Boskabady, M. H., & Snashall, P. D. (2000). Bronchial responsiveness to beta-adrenergic stimulation and enhanced beta blockade in asthma. Respirology, 5(2), 111-118. DOI: 10.1046/j.1440-1843.2000.00243.x. Boskabady, M. H., & Moemeni, A. (2000). Stimulatory effect of Carum copticum on beta2 adrenoceptors of isolated guinea pig tracheal chains. Medical Journal of the Islamic Republic of Iran, 13(3), 273-278. DOI: 10.17102/mjiri.2000.0192. Boskabady, M. H., Karbandy, S., & Abedinzadah, A. (2000). The effects of arterial O2 saturation and heart rate on blood pressure. Medical Journal of the Islamic Republic of Iran, 14(2), 37-41. DOI: 10.17102/mjiri.2000.0200. Boskabady, M. H., & Karimian, M. (2000). Prevalence of asthma among guidance school students (aged 11-16 years) in the city of Mashhad (north east of Iran). Archives of Iranian Medicine, 3(3), 165-169. DOI: 10.30476/aim.2000.0109. Boskabady, M. H., & Hosaini, M. (2000). Effect of patient education and regular PEF measurement on self-management of asthma. Iranian Journal of Allergy, Asthma, and Immunology, 1(2), 159-164. DOI: 10.30476/ijaai.2000.0111. Boskabady, M. H., & Ramazani, M. (2001). Relaxant effect of Pimpinella anisum on isolated guinea pig tracheal chains and its possible mechanism(s). Journal of Ethnopharmacology, 74(1), 83-88. DOI: 10.1016/S0378-8741(00)00382-5. Boskabady, M. H., Keshmiri, M., Banihashemi, B., & Anvary, K. H. (2002). Lung function values in healthy non-smoking urban adults in Iran. Respiration, 69(4), 320-326. DOI: 10.1159/000065155. Boskabady, M. H., & Klahdoz, G. H. (2002). Prevalence of asthma symptoms among the adult population in the city of Mashhad (north-east of Iran). Respirology, 7(3), 267-272. DOI: 10.1046/j.1440-1843.2002.00413.x. Boskabady, M. H., & Shirmohammadi, B. (2002). Effect of Nigella sativa on isolated guinea pig trachea. Archives of Iranian Medicine, 5(2), 103-107. DOI: 10.30476/aim.2002.0145. Boskabady, M. H., & Shiravi, N. (2002). Inhibitory effect of Nigella sativa on histamine (H1) receptors of isolated guinea pig tracheal chains. Pharmaceutical Biology, 40(8), 596-602. DOI: 10.1076/1388-0209(200208)4008-0005.
Dr. David Haefliger | Pharmacology | Best Researcher Award Posted on 27/08/202427/08/2024 by ScienceFather Dr. David Haefliger | Pharmacology | Best Researcher Award Dr. David Haefliger, CHUV, Switzerland Dr. David Haefliger is a distinguished expert in pharmacology, recognized for his groundbreaking research and contributions to the field. With a strong background in drug interactions and therapeutic efficacy, Dr. Haefliger’s work has significantly advanced the understanding of pharmacological mechanisms and their clinical applications. His research is widely published in leading journals and has been instrumental in shaping contemporary practices in pharmacology. As a recipient of the Best Researcher Award, Dr. Haefliger continues to drive innovation and excellence in his field, demonstrating an unwavering commitment to advancing medical science and improving patient outcomes. Profile Scoopus Education Dr. David Haefliger has an extensive educational and professional background in the medical field. He earned his Bachelor’s degree in Medicine in June 2012 and his Master’s degree in Medicine in June 2015, both from the University of Lausanne, Switzerland. In addition to his foundational degrees, he completed the Swiss Board Examination in General Internal Medicine in June 2019, and he is an Advanced Cardiovascular Life Support Provider, certified in October 2016. Most recently, in 2024, Dr. Haefliger obtained a Certificate of Advanced Studies in Clinical Research from the University of Lausanne, further solidifying his expertise and commitment to advancing clinical research. Proffesional Experience Since February 2022, Dr. David Haefliger has been working in the Service of Clinical Pharmacology at the Department of Medicine, University Hospital Lausanne, Switzerland. Prior to this role, he served in the Service of Infectious Diseases at the University Hospital Lausanne from November 2019 to October 2021. Dr. Haefliger also gained valuable experience in the Intensive Care Unit at Fribourg Hospital from November 2018 to October 2019. His career began in Internal Medicine at Fribourg Hospital, where he worked from November 2015 to October 2018. Publication Top Notes Haefliger D, Chehade H, Livio F, Rodrigues-Veiga V, Diezi L, Marzolini C. Vancomycin Dosing Strategy for the Treatment of Peritonitis in a Child on Automated Peritoneal Dialysis: A First Pediatric Case Report. Semin Dial. 2024. Dao K, Buettcher M, Golhen K, et al. Novel Patient-Friendly Orodispersible Formulation of Ivermectin is Associated With Enhanced Palatability, Controlled Absorption, and Less Variability: High Potential for Pediatric Use. J Clin Pharmacol. 2024. Dao K, Shechtman S, Weber-Schoendorfer C, et al. Use of GLP-1 Receptor Agonists in Early Pregnancy and Reproductive Safety: A Multicentre, Observational, Prospective Cohort Study Based on the Databases of Six Teratology Information Services. BMJ Open. 2024. Grütter S, Haefliger D, Wuerzner G, Yerly P, Bouchardy J, Rutz T. The Deleterious Consequences of a Nonsteroidal Anti-inflammatory Drug in an Eisenmenger Patient. CJC Pediatr Congenit Heart Dis. 2023. Haefliger D, Marzolini C, Lamoth F, Pabst T, Buclin T, Livio F. Clinically Relevant Bidirectional Drug-Drug Interaction Between Midostaurin and Voriconazole. Br J Clin Pharmacol. 2023. Haefliger D, Livio F. Pharmacothérapie – Nouveaux Médicaments et Vaccins Disponibles en 2022 [Pharmacotherapy: New Drugs and Vaccines in 2022]. Rev Med Suisse. 2023. Desgranges F, Tadini E, Munting A, et al. Post-COVID-19 Syndrome in Outpatients: A Cohort Study. J Gen Intern Med. 2022. Regina J, Papadimitriou-Olivgeris M, Burger R, et al. Epidemiology, Risk Factors, and Clinical Course of SARS-CoV-2 Infected Patients in a Swiss University Hospital: An Observational Retrospective Study. PLoS One. 2020. Grandjean T, Haefliger D, Arroyo D, Cook S. Coronary Sinus Reduction for the Treatment of Refractory Angina. Cardiovasc Med. 2018. Haefliger D, Chuard C. Légionellose [Legionellosis]. Rev Med Suisse. 2017. Articles with Acknowledgments (as a member of the RegCOVID Study Group): Galperine T, Choi Y, Pagani JL, et al. Temporal Changes in Fecal Microbiota of Patients Infected with COVID-19: A Longitudinal Cohort. BMC Infect Dis. 2023. COVID-19 Host Genetics Initiative. Mapping the Human Genetic Architecture of COVID-19. Nature. 2021. Bibert S, Guex N, Lourenco J, et al. Transcriptomic Signature Differences Between SARS-CoV-2 and Influenza Virus Infected Patients. Front Immunol. 2021.
Dr. David Haefliger is a distinguished expert in pharmacology, recognized for his groundbreaking research and contributions to the field. With a strong background in drug interactions and therapeutic efficacy, Dr. Haefliger’s work has significantly advanced the understanding of pharmacological mechanisms and their clinical applications. His research is widely published in leading journals and has been instrumental in shaping contemporary practices in pharmacology. As a recipient of the Best Researcher Award, Dr. Haefliger continues to drive innovation and excellence in his field, demonstrating an unwavering commitment to advancing medical science and improving patient outcomes. Profile Scoopus Education Dr. David Haefliger has an extensive educational and professional background in the medical field. He earned his Bachelor’s degree in Medicine in June 2012 and his Master’s degree in Medicine in June 2015, both from the University of Lausanne, Switzerland. In addition to his foundational degrees, he completed the Swiss Board Examination in General Internal Medicine in June 2019, and he is an Advanced Cardiovascular Life Support Provider, certified in October 2016. Most recently, in 2024, Dr. Haefliger obtained a Certificate of Advanced Studies in Clinical Research from the University of Lausanne, further solidifying his expertise and commitment to advancing clinical research. Proffesional Experience Since February 2022, Dr. David Haefliger has been working in the Service of Clinical Pharmacology at the Department of Medicine, University Hospital Lausanne, Switzerland. Prior to this role, he served in the Service of Infectious Diseases at the University Hospital Lausanne from November 2019 to October 2021. Dr. Haefliger also gained valuable experience in the Intensive Care Unit at Fribourg Hospital from November 2018 to October 2019. His career began in Internal Medicine at Fribourg Hospital, where he worked from November 2015 to October 2018. Publication Top Notes Haefliger D, Chehade H, Livio F, Rodrigues-Veiga V, Diezi L, Marzolini C. Vancomycin Dosing Strategy for the Treatment of Peritonitis in a Child on Automated Peritoneal Dialysis: A First Pediatric Case Report. Semin Dial. 2024. Dao K, Buettcher M, Golhen K, et al. Novel Patient-Friendly Orodispersible Formulation of Ivermectin is Associated With Enhanced Palatability, Controlled Absorption, and Less Variability: High Potential for Pediatric Use. J Clin Pharmacol. 2024. Dao K, Shechtman S, Weber-Schoendorfer C, et al. Use of GLP-1 Receptor Agonists in Early Pregnancy and Reproductive Safety: A Multicentre, Observational, Prospective Cohort Study Based on the Databases of Six Teratology Information Services. BMJ Open. 2024. Grütter S, Haefliger D, Wuerzner G, Yerly P, Bouchardy J, Rutz T. The Deleterious Consequences of a Nonsteroidal Anti-inflammatory Drug in an Eisenmenger Patient. CJC Pediatr Congenit Heart Dis. 2023. Haefliger D, Marzolini C, Lamoth F, Pabst T, Buclin T, Livio F. Clinically Relevant Bidirectional Drug-Drug Interaction Between Midostaurin and Voriconazole. Br J Clin Pharmacol. 2023. Haefliger D, Livio F. Pharmacothérapie – Nouveaux Médicaments et Vaccins Disponibles en 2022 [Pharmacotherapy: New Drugs and Vaccines in 2022]. Rev Med Suisse. 2023. Desgranges F, Tadini E, Munting A, et al. Post-COVID-19 Syndrome in Outpatients: A Cohort Study. J Gen Intern Med. 2022. Regina J, Papadimitriou-Olivgeris M, Burger R, et al. Epidemiology, Risk Factors, and Clinical Course of SARS-CoV-2 Infected Patients in a Swiss University Hospital: An Observational Retrospective Study. PLoS One. 2020. Grandjean T, Haefliger D, Arroyo D, Cook S. Coronary Sinus Reduction for the Treatment of Refractory Angina. Cardiovasc Med. 2018. Haefliger D, Chuard C. Légionellose [Legionellosis]. Rev Med Suisse. 2017. Articles with Acknowledgments (as a member of the RegCOVID Study Group): Galperine T, Choi Y, Pagani JL, et al. Temporal Changes in Fecal Microbiota of Patients Infected with COVID-19: A Longitudinal Cohort. BMC Infect Dis. 2023. COVID-19 Host Genetics Initiative. Mapping the Human Genetic Architecture of COVID-19. Nature. 2021. Bibert S, Guex N, Lourenco J, et al. Transcriptomic Signature Differences Between SARS-CoV-2 and Influenza Virus Infected Patients. Front Immunol. 2021.
Since February 2022, Dr. David Haefliger has been working in the Service of Clinical Pharmacology at the Department of Medicine, University Hospital Lausanne, Switzerland. Prior to this role, he served in the Service of Infectious Diseases at the University Hospital Lausanne from November 2019 to October 2021. Dr. Haefliger also gained valuable experience in the Intensive Care Unit at Fribourg Hospital from November 2018 to October 2019. His career began in Internal Medicine at Fribourg Hospital, where he worked from November 2015 to October 2018. Publication Top Notes Haefliger D, Chehade H, Livio F, Rodrigues-Veiga V, Diezi L, Marzolini C. Vancomycin Dosing Strategy for the Treatment of Peritonitis in a Child on Automated Peritoneal Dialysis: A First Pediatric Case Report. Semin Dial. 2024. Dao K, Buettcher M, Golhen K, et al. Novel Patient-Friendly Orodispersible Formulation of Ivermectin is Associated With Enhanced Palatability, Controlled Absorption, and Less Variability: High Potential for Pediatric Use. J Clin Pharmacol. 2024. Dao K, Shechtman S, Weber-Schoendorfer C, et al. Use of GLP-1 Receptor Agonists in Early Pregnancy and Reproductive Safety: A Multicentre, Observational, Prospective Cohort Study Based on the Databases of Six Teratology Information Services. BMJ Open. 2024. Grütter S, Haefliger D, Wuerzner G, Yerly P, Bouchardy J, Rutz T. The Deleterious Consequences of a Nonsteroidal Anti-inflammatory Drug in an Eisenmenger Patient. CJC Pediatr Congenit Heart Dis. 2023. Haefliger D, Marzolini C, Lamoth F, Pabst T, Buclin T, Livio F. Clinically Relevant Bidirectional Drug-Drug Interaction Between Midostaurin and Voriconazole. Br J Clin Pharmacol. 2023. Haefliger D, Livio F. Pharmacothérapie – Nouveaux Médicaments et Vaccins Disponibles en 2022 [Pharmacotherapy: New Drugs and Vaccines in 2022]. Rev Med Suisse. 2023. Desgranges F, Tadini E, Munting A, et al. Post-COVID-19 Syndrome in Outpatients: A Cohort Study. J Gen Intern Med. 2022. Regina J, Papadimitriou-Olivgeris M, Burger R, et al. Epidemiology, Risk Factors, and Clinical Course of SARS-CoV-2 Infected Patients in a Swiss University Hospital: An Observational Retrospective Study. PLoS One. 2020. Grandjean T, Haefliger D, Arroyo D, Cook S. Coronary Sinus Reduction for the Treatment of Refractory Angina. Cardiovasc Med. 2018. Haefliger D, Chuard C. Légionellose [Legionellosis]. Rev Med Suisse. 2017. Articles with Acknowledgments (as a member of the RegCOVID Study Group): Galperine T, Choi Y, Pagani JL, et al. Temporal Changes in Fecal Microbiota of Patients Infected with COVID-19: A Longitudinal Cohort. BMC Infect Dis. 2023. COVID-19 Host Genetics Initiative. Mapping the Human Genetic Architecture of COVID-19. Nature. 2021. Bibert S, Guex N, Lourenco J, et al. Transcriptomic Signature Differences Between SARS-CoV-2 and Influenza Virus Infected Patients. Front Immunol. 2021.